DALLAS, Aug. 19, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Cell Therapeutics Inc. (Nasdaq:CTIC). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Cell Therapeutics Inc. (Nasdaq:CTIC) should be of particular interest to biopharmaceutical companies: Abraxis BioSciences Inc. (Nasdaq:ABII), Teva Pharmaceuticals (Nasdaq:TEVA), Live Technologies Corp. (Nasdaq:LIFE) and Gilead Sciences Inc. (Nasdaq:GILD).
It is available at: http://www.stockpreacher.com/n/CTIC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Cell Therapeutics Inc. (CTIC) is a biopharmaceutical company engaged in the development and commercialization of oncology drug therapies for the treatment of cancer. Its portfolio of trial therapies include phase III candidate drug therapy Pixantrone, for the treatment of non-Hodgkin's lymphoma; phase II drug Brostallicin, for the treatment of sarcoma; and OPAXIO for the treatment of non-small cell lung, ovarian, and other forms of cancer. The Company partnered with Novartis International Pharmaceuticals Ltd. and PG-TXL Company L.P. for various drug developments.
In the report, the analyst notes:
"If approved by the U.S. Food and Drug Administration (FDA), the market for CTIC's drug candidate Pixantrone, could reach more than $1 billion at its market saturation. Brostallicin is the Company's phase II drug candidate for the treatment of sarcoma, with prospects of reaching commercialization at approximately 50% following successful completion of phase II.
"On June 30, the Company announced it was included in the Russell 3000, Russell 2000, and Russell Global Indexes. On June 24, the Company submitted necessary paperwork for its non-Hodgkin's lymphoma drug candidate Pixantrone."
To read the entire report visit: http://www.stockpreacher.com/n/CTIC
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions and information free of charge exclusively to individuals who wish to receive them. Please read our report and visit our Website, StockPreacher.com, for complete risks and disclosures.